Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-09-2017 | Original Article

Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center

Authors: Yakup Bozkaya, Doğan Uncu, Simten Dağdaş, Gökmen Umut Erdem, Mutlu Doğan, Gülsüm Özet, Nurullah Zengin

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2017

Abstract

The aim of this study is to evaluate the results of relapsed or refractory Hodgkin (HL) and non-Hodgkin Lymphomas (NHL) patients who underwent autologous stem cell transplantation supported high-dose chemotherapy (HDC–ASCT). Forty patients who received HDC–ASCT between November 2004 and February 2014 for relapsed or refractory HL and NHL were analysed retrospectively. There were 22 patients with HL and 18 patients with NHL. Thirty-eight patients could be evaluated after transplantation, as two of the patients died in the early post-transplantation period. We identified complete response in 24 patients (63%), partial response in 8 patients (21%), stable disease in 4 patients (11%) and progressive disease in 2 patients (5%). In all patient groups, 5-year overall survival (OS) and event free survival (EFS) were 43 and 40%, respectively; however there was no statistically significant survival difference between HL and NHL patients after ASCT, and 5-year OS and EFS were 47, 40 and 53%, 23%, respectively (p = 0.43, p = 0.76). Chemosensitive relapse had a positive impact on OS (p = 0.02). This study provides evidence for the effectiveness of HDC–ASCT as salvage therapy for patients with relapsed/refractory NHL and HL. Chemosensitive relapse is the most important prognostic factor determining the outcome of the ASCT.

Oza AM, Ganesan TS, Leahy M, Gregory W, Lim J, Dadiotis L, Barbounis V, Jones AE, Amess J, Stansfeld AG (1993) Patterns of survival in patients with Hodgkin’ s disease: long follow up in a single center. Ann Oncol 4:385–392CrossRefPubMed

Viviani S, Bonadonna G, Santoro A, Bınfante V, Zanini M, Devizzi L, Soncini F, Valagussa P (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’ s disease: ten year results. J Clin Oncol 14:1421–1430CrossRefPubMed

Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D (2010) Allogeneic and autologous transplantation for haematological diseases, solidtumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 45:219–234

Ayala E, Tomblyn M (2011) Hematopoietic cell transplantation for lymphomas. Cancer Control 18(4):246–257PubMed

Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A (2005) Cologne high dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group(GHSG). Ann Oncol 16:116–123CrossRefPubMed

Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D, Kaminer L, Williams S, Duffey S, Variakojis D, Singhal S, Tallman MS, Mehta J, Winter JN, Gordon LI (2007) Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Ann Oncol 18:679–688CrossRefPubMed

Morton LM, Wang SS, Devesa SS, Hardge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276CrossRefPubMedPubMedCentral

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with RCHOP. Blood 109:1957–1961

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105–116CrossRefPubMed

10.

Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Frevtes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM (2001) Autologus transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406–413CrossRefPubMed

11.

Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH (2000) High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 96:2399–2404PubMed

12.

Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A, Pastor M (1999) ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 10:593–595CrossRefPubMed

13.

Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 124:645–652CrossRefPubMed

14.

Ferme C, Mounier N, Divine M, Brice P, Stamatoullas Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de I’Adulte H89 Trial. J Clin Oncol 20:467–475PubMed

15.

Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E (2004) High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 34:581–587CrossRefPubMed

16.

Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ (2005) High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106:1473–1478CrossRefPubMed

17.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

18.

Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218CrossRefPubMed

19.

Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054CrossRefPubMed

20.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545CrossRefPubMed

21.

Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D (1993) High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol 11:704–711CrossRefPubMed

22.

Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A (2008) Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 19:1312–1319CrossRefPubMed

23.

Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM (2010) Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma 51:1251–1259CrossRefPubMed

24.

Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, López A, Lahuerta JJ, Carreras E, García-Conde J, García-Laraña J, Cabrera R, Jarque I, Carrera D, García-Ruiz JC, Pascual MJ, Rifón J, Moraleda JM, Pérez-Equiza K, Albó C, Díaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marín J, Mateos MV, Fernández-Rañada JM, Sierra J, Conde E (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 16:625–633CrossRefPubMed

25.

Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J, Gozdzik J, Hansz J, Avigdor A, Nagler A, Osowiecki M, Walewski J, Mensah P, Jurczak W, Skotnicki A, Sedzimirska M, Lange A, Sawicki W, Sulek K, Wach M, Dmoszynska A, Kus A, Robak T, Warzocha K (2004) Outcome and prognostic factors in advanced Hodgkin’s disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. Ann Oncol 15:1222–1230CrossRefPubMed

26.

Kaiser U, Uebelacker I, Abel U (2002) Randomised study to evaluate the use of high-dose therapy as part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2:4413–4419CrossRef

27.

Josting A, Reiser M, Rueffler U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 18:332–339CrossRefPubMed

28.

Chang H, Cheong JW, Hahn JS (2006) High dose chemotherapy and autologous stem cell transplantation in non-Hodgkin’s Lymphoma: an eight-year experience. Yonsei Med J 47:604–613CrossRefPubMedPubMedCentral

29.

Radman I, Basic N, Labar B, Kovacevic J, Aurer I, Bogdanic V, Zupancić-Salek S, Nemet D, Jakić-Razumović J, Mrsić M, Santek F, Grgić-Markulin L, Boban D (2002) Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin’s disease (Croatian experience). Ann Oncol 13:1650–1655CrossRefPubMed

30.

Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96:1280–1286PubMed

31.

Sweetenham JW, Carella AM, Taghipour G, Cunninqham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH (1999) High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17:3101–3109CrossRefPubMed

32.

Sucak GT, Çakar MK, Suyanı E, Akı Z, Altındal Ş, Acar K (2013) Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology 18:269–276CrossRefPubMed

33.

Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM (2005) High-dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 23:7994–8002CrossRefPubMed

34.

Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J, Jarque I, Caballero MD, Ferrà C, López A, García-Laraña J, Cabrera R, Carrera D, Ruiz-Romero MD, León A, Rifón J, Díaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Altés A, López-Guillermo A, de la Serna J, Fernández-Rañada JM, Sierra J, Conde E (2001) Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol 19:1395–1404CrossRefPubMed

35.

Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ (2006) Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12:1065–1072CrossRefPubMed

Title: Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center
Authors: Yakup Bozkaya
Doğan Uncu
Simten Dağdaş
Gökmen Umut Erdem
Mutlu Doğan
Gülsüm Özet
Nurullah Zengin
Publication date: 01-09-2017
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 3/2017
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-016-0756-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Pharmacogenetics and Personalized Medicine in Hematology

Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia

Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders

Oleuropein Ameliorates Cisplatin-induced Hematological Damages Via Restraining Oxidative Stress and DNA Injury

Evaluation of Iron Overload in the Heart and Liver Tissue by Magnetic Resonance Imaging and its Relation to Serum Ferritin and Hepcidin Concentrations in Patients with Thalassemia Syndromes

Unilateral Gynaecomastia in a Young Man with Chronic Myeloid Leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer